Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.56 |
| ▸ | STS | P08842 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23130983 | 0.91 | GPR119 (0.50) | NAMPTGPR119STSKDM4EPKM | |
| SCHEMBL3843148 | 0.89 | NAMPT (0.66) | NAMPTGPR119STSKDM4EPKM | |
| SCHEMBL21714300 | 0.88 | GPR119 (0.51) | NAMPTGPR119STSKDM4ETP53 | |
| SCHEMBL21714163 | 0.87 | STS (0.56) | NAMPTGPR119STSKDM4ELMNA | |
| SCHEMBL21714105 | 0.86 | NAMPT (0.52) | NAMPTGPR119STSKDM4ETHRB | |
| Acetic Acid SCHEMBL29880486 | 0.86 | NAMPT (0.63) | NAMPTGPR119STSKDM4EPKM | |
| Dimethylamine SCHEMBL6608623 | 0.85 | NAMPT (0.65) | NAMPTGPR119STSKDM4EPKM | |
| Trifluoroacetic Acid SCHEMBL29880449 | 0.83 | NAMPT (0.60) | NAMPTGPR119STSKDM4EPKM | |
| SCHEMBL23153250 | 0.82 | TP53 (0.47) | NAMPTGPR119TP53LMNA | |
| SCHEMBL22050474 | 0.81 | NAMPT (0.64) | NAMPTGPR119STSKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | E-THERAPEUTICS PLC (GB) | 2021-03-30 | — | — | US | claimed |
| US-20200055847-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | E-THERAPEUTICS PLC (GB) | 2020-02-20 | — | — | US | claimed |
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | E-THERAPEUTICS PLC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | E-THERAPEUTICS PLC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200055847-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | E-THERAPEUTICS PLC (GB) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | SHH, GLI1, SMO | NAMPT 3068/4885GPR119 276/4885STS 2834/4885 |
| US-20200055847-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | SHH, GLI1, SMO | NAMPT 3126/4885GPR119 261/4885STS 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.